Home  >  TopNews
Msc_Apr23 .
you can get e-magazine links on WhatsApp. Click here
Hospitals & Clinics + Font Resize -

Shalby Hospitals eyeing growth target of 20% for FY2022; to add 321 beds

Yash Ved, Mumbai
Wednesday, December 8, 2021, 08:00 Hrs  [IST]

Shalby Limited, which operates India’s leading chain of multi-specialty hospitals under Shalby Hospitals brand, stated that it is eyeing growth target of 20% and EBITDA margins at 22-24% for FY2022.

The company stated that it is planning to add additional 321 beds to current capacity and are going to incur cost of Rs. 1,910 million to add above capacity beds.

The company will be aiming to add more than 50 such franchises across India in next 3-4 years.

The company also stated that it will be adding two hospitals in its hospital business, which will be located at Nashik and Santacruz in Mumbai and will be operationalized by FY23 and FY24 respectively. Santacruz hospital in Mumbai will have 175 beds capacity and Nashik will have 146 beds capacity.  

“We have been focusing more on asset light model and going with Franchise options with SOCE - Shalby Orthopedics Centre of Excellence. Under this, we are rolling our two separate models i.e., Franchise owned and Franchise Operated (FOFO) and Franchise Owned and Shalby Operated (FOSO). The objective is to leverage Shalby’s core competence speciality i.e. Orthopaedics and providing technical expertise to these Franchises, which will be focusing mainly on Orthopedic branch of speciality,” Shanay Shah, President, Shalby Ltd. said.

Shah added, “We have recently made an asset purchase by acquiring the implant assets, inventory and patents of Consensus Orthopaedics located at Sacramento in USA, which will eventually create a backward integration and produce more synergies to our existing business.”

The company posted 53.5% rise in total income at Rs.1,717 million for the second quarter ended September 30, 2021.The company's operating EBITDA stood at Rs. 345 million with EBITDA margins of 20.1%.

"Overall, the performance during the quarter was underpinned by growth in core specialties such as arthroplasty, orthopedics, oncology and cardiac science which contributed 37%, 11%, 8% and 8% to the revenues, respectively. On a consolidated level, Shalby continues to remain net cash positive to support future growth plans. Furthermore, we are proud to deliver double digit ROCE of 11.6% on H1 FY22 annualized basis,” stated Shah.

Shah added, "Our hospital business is currently having Rs. 40 crore of debt levels against the healthy cash and investment of Rs. 160 crore as on 30th September 2021 at group level. We have recently added Rs. 110 crore of term loan and working capital facility for our implant business in Shalby Advanced Technologies Inc."

Shalby Limited currently operates a chain of 11 multispecialty tertiary hospitals across India with an aggregate bed capacity of over 2,000 hospital beds. Shalby has a 3,000 plus in-house team of skilled doctors, surgeons and support staff with relevant industry experience and in-depth domain expertise. It is one of the top hospitals in joint replacement surgery in India with 15% market share in private hospitals offering joint replacement and 5% overall market share.


* Name :     
* Email :    
  Website :  
Pharma live expo
Copyright © 2023 Saffron Media Pvt. Ltd |